The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ELDN | -58.47% | -89.86% | -36.7% | -96% |
| S&P | +12.65% | +91.73% | +13.89% | +181% |
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cellular transplant, and for people living with autoimmune and neurodegenerative disease. The firm’s compound in development is AT-1501, a humanized IgG1 anti-CD40L antibody with high affinity for CD40 ligand (CD40L, also called CD154), a well-validated biological target with broad therapeutic potential. The CD40L/CD40 pathway is recognized for its prominent role in immune regulation, making it a candidate for therapeutic intervention in transplant tolerance, autoimmune disease, and neuro-inflammation. The company is building upon a deep historical understanding of the CD40/CD40L pathway, as well as preclinical and Phase 1 data, to initiate up to four phase 2 clinical studies with AT-1501. Eledon Pharmaceuticals was founded on March 26, 2004 and is headquartered in Irvine, CA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | $0.00M | 100.0% |
| Market Cap | $162.28M | 59.6% |
| Market Cap / Employee | $5.23M | 0.0% |
| Employees | 31 | 55.0% |
| Net Income | -$11.22M | 75.0% |
| EBITDA | -$24.73M | -71.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $5.74M | -78.0% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.47M | 21.0% |
| Short Term Debt | $0.34M | 24.9% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -5.95% | 139.0% |
| Return On Invested Capital | -356.84% | 27.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$17.71M | -127.8% |
| Operating Free Cash Flow | -$17.71M | -127.8% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -11.28 | 2.23 | 1.72 | 1.42 | -131.84% |
| Price to Tangible Book Value | -2.35 | 3.89 | 2.36 | 1.97 | -242.00% |
| Enterprise Value to EBITDA | -2.96 | -4.35 | -7.65 | -6.39 | 221.12% |
| Return on Equity | -119.4% | -93.7% | -83.3% | -16.2% | -95.50% |
| Total Debt | $0.50M | $0.95M | $0.88M | $0.80M | 22.60% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
